ClinicalTrials.gg
CompletedNCT00948090Updated Jul 31, 2014Results posted

PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients

A Phase 2 interventional study of IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen) in Lymphoma, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 42 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-31.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
207
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing busulfan in Lymphoma — 2 open to participants now, 6 under way, none of them phase 3. Busulfan · Lymphoma.

Enrollment
5th of 63
207 · median 47
Started
2010
with 5 others
Phase 2
41 of 64
2 open now
Registered
41st of 64
by date

Among the 64 studies testing busulfan in Lymphoma, this one is the 5th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2010, is one of 41 in phase 2, and was the 41st registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

2 of the 64 studies testing busulfan in Lymphoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About busulfan

Busulfan: first FDA approval 1954 (MYLERAN), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing busulfan in Lymphoma, or all of them as a file.
02

Study summary

This is a study for the outcome and safety of individualized busulfan dosing with cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat Non-Hodgkin or Hodgkin's Lymphoma.

Read the detailed description

Evaluation of progression-free survival, transplant related mortality, overall survival, and overall response rate, in subjects with NHL and HL receiving an IV busulfan-based conditioning regimen with PK-guided IV busulfan dosing, followed by autologous HSCT as well as comparison to those receiving carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning regimen (and its variants) obtained from registry data in the Center for International Blood and Marrow Transplant Research (CIBMTR) Assessment of the safety profile of a BuCyE conditioning regimen with PK-directed dosing of IV busulfan will also be completed.

03

Conditions studied

  • Lymphoma

Keywords

  • Hodgkin Lymphoma
  • Non-Hodgkin's Lymphoma
  • Bone marrow transplant
  • stem cell transplant
  • busulfan
  • cyclophosphamide
  • etoposide
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects with NHL to be included:

  • Any subject with NHL that had or progressed following initial therapy with an anthracycline-based chemotherapy regimen and has achieved a subsequent partial remission (PR) or a complete remission (CR) following a salvage chemotherapy regimen.
  • Any subject with NHL that was initially refractory to an anthracycline-based chemotherapy regimen but who has achieved a PR or CR following a salvage chemotherapy regimen.
  • Any subject with an initial International Prognostic Index (IPI) score 4-5 who achieved a PR or any CR following an anthracycline-based chemotherapy regimen except subjects with Mantle cell, T cell and Natural Killer (NK) cell pathologies.
  • Subjects with Mantle cell, T cell and NK cell lymphoma may be enrolled if they have PR or CR after initial therapy.
  • Any subject that has relapsed or progressed following previous HSCT.

Subjects with HL to be included:

  • Any subject with HL that had relapsed or progressed following initial therapy with an multi-drug chemotherapy regimen and has achieved a subsequent PR or a CR following a salvage chemotherapy regimen.
  • Any subject with HL that is initially refractory to a multi-drug chemotherapy regimen but who has achieved a PR or CR following a salvage chemotherapy regimen.
  • Any subject that has relapsed or progressed following previous autologous HSCT.

Exclusion criteria

Exclusion Criteria:

  • Any subject with chemoresistant disease by demonstration of less than PR to most recent chemotherapy, and any subject with prior treatment history of HSCT or high-dose chemotherapy with stem cell rescue for any medical reason will be excluded.

Excluded will also be subjects with existing or active central nervous system lymphoma or related lymphoma, unacceptable organ function, or uncontrolled infections.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    IV Busulfan

    Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant

    Drug: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)

Interventions

  • DrugIV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)

    Drug pages: Busulfan · Cyclophosphamide · Etoposide

    Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.

06

What researchers measure

Primary outcomes

  1. Number of Progression Events in 2 Years.

    The time of Progression-Free Survival (PFS) was defined as the time from transplantation to the occurrence of the event that was death or first recurrence of progressive disease.

    Time frame: 2 years

Secondary outcomes

  1. Number of Death Events in 2 Years.

    The time of overall survival was defined as the time from transplantation to death of all causes.

    Time frame: 2 years

  2. Number of Transplant-related Death Events Until Day 100.

    Transplant-related mortality was defined as death due to any cause other than disease relapse/progression up until Day 100.

    Time frame: Day 100

  3. Overall Response Rate

    The overall response status is complete response and not complete response (partial remission, primary refractory/primary induction failure, stable disease, progressive disease, and relapse) at Baseline and each of the scheduled follow-up time points.

    Time frame: Baseline, Day 100, Month 6, 12, 24, Early termination and End of Trial (within 30 days of the trial termination)

07

Results

Posted Jul 31, 2014

Participant flow

A multicenter (43 trial sites in United States and Canada), single-arm, open-label, phase 2 exploratory trial to evaluate clinical outcomes following pharmacokinetic (PK)-directed intravenous (IV) busulfan therapy in 207 participants with Non-Hodgkin's and Hodgkin's lymphoma were evaluated.

Participant flow — Overall Study
MilestoneHodgkin's Lymphoma (≤ 65 Years)Hodgkin's Lymphoma (> 65 Years)Non-Hodgkin's Lymphoma (≤ 65 Years)Non-Hodgkin's Lymphoma (> 65 Years)
Started65112318
Completed220677
Not completed4315611

Outcome measures

PrimaryNumber of Progression Events in 2 Years.

The time of Progression-Free Survival (PFS) was defined as the time from transplantation to the occurrence of the event that was death or first recurrence of progressive disease.

Time frame:
2 years
Reported as:
Number · Event
Number of Progression Events in 2 Years.
EventHodgkin's Lymphoma (≤ 65 Years)Hodgkin's Lymphoma (> 65 Years)Non-Hodgkin's Lymphoma (≤ 65 Years)Non-Hodgkin's Lymphoma (> 65 Years)
Number of Progression Events in 2 Years.411468
SecondaryNumber of Death Events in 2 Years.

The time of overall survival was defined as the time from transplantation to death of all causes.

Time frame:
2 years
Reported as:
Number · Deaths
Number of Death Events in 2 Years.
DeathsHodgkin's Lymphoma (≤ 65 Years)Hodgkin's Lymphoma (> 65 Years)Non-Hodgkin's Lymphoma (≤ 65 Years)Non-Hodgkin's Lymphoma (> 65 Years)
Number of Death Events in 2 Years.131286
SecondaryNumber of Transplant-related Death Events Until Day 100.

Transplant-related mortality was defined as death due to any cause other than disease relapse/progression up until Day 100.

Time frame:
Day 100
Reported as:
Number · Transplant-related death
Number of Transplant-related Death Events Until Day 100.
Transplant-related deathHodgkin's Lymphoma (≤ 65 Years)Hodgkin's Lymphoma (> 65 Years)Non-Hodgkin's Lymphoma (≤ 65 Years)Non-Hodgkin's Lymphoma (> 65 Years)
Number of Transplant-related Death Events Until Day 100.1153
SecondaryOverall Response Rate

The overall response status is complete response and not complete response (partial remission, primary refractory/primary induction failure, stable disease, progressive disease, and relapse) at Baseline and each of the scheduled follow-up time points.

Time frame:
Baseline, Day 100, Month 6, 12, 24, Early termination and End of Trial (within 30 days of the trial termination)
Reported as:
Number · Participants
Overall Response Rate
ParticipantsHodgkin's Lymphoma (≤ 65 Years)Hodgkin's Lymphoma (> 65 Years)Non-Hodgkin's Lymphoma (≤ 65 Years)Non-Hodgkin's Lymphoma (> 65 Years)
Baseline-Complete Response (N=65, 0, 121, 16)3507212
Baseline-Not Complete Response (N=65, 1, 121, 16)301494
Day 100-Complete Response (N=57, 0, 114, 12)350858
Day 100-Not Complete Response (N=57, 0, 114, 12)220294
Month 6-Complete Response (N=45, 0, 98, 11)300849
Month 6-Not Complete Response (N=45, 0, 98, 11)150142
Month 12-Complete Response (N=32, 0, 88, 8)220718
Month 12-Not Complete Response (N=32, 0, 88, 0)100170
Month 24-Complete Response (N=13, 0, 28, 6)110266
Month 24-Not Complete Response (N=13, 0, 28, 0)2020
Early Term-Complete Response (N=40, 0, 41, 0)2040
Early Term-Not Complete Response (N=40, 0, 41, 5)380375
End of Trial-Complete Response (N=22, 0, 71, 9)200658
End of Trial-Not Complete Response(N=22, 0, 71, 9)2061

Adverse events

Collected over Adverse events were reported during the entire trial period (from screening through Early Termination or End of Trial).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hodgkin's/Non-Hodgkin's Lymphoma (≤ 65 Years or > 65 Years)—90/207 (43.5%)190/207 (91.8%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventHodgkin's/Non-Hodgkin's Lymphoma (≤ 65 Years or > 65 Years)
Febrile neutropeniaBlood and lymphatic system disorders9/207
PyrexiaGeneral disorders9/207
PneumoniaInfections and infestations9/207
SepsisInfections and infestations8/207
HypotensionVascular disorders7/207
StomatitisGastrointestinal disorders6/207
Renal failure acuteRenal and urinary disorders6/207
Atrial fibrillationCardiac disorders5/207
Septic shockInfections and infestations4/207
DehydrationMetabolism and nutrition disorders4/207
Most frequent other events
Showing 10 of 99
Most frequent other events
EventHodgkin's/Non-Hodgkin's Lymphoma (≤ 65 Years or > 65 Years)
DiarrhoeaGastrointestinal disorders179/207
StomatitisGastrointestinal disorders170/207
NauseaGastrointestinal disorders169/207
VomitingGastrointestinal disorders132/207
Febrile neutropeniaBlood and lymphatic system disorders129/207
FatigueGeneral disorders104/207
HypokalaemiaMetabolism and nutrition disorders100/207
PyrexiaGeneral disorders94/207
Decreased appetiteMetabolism and nutrition disorders94/207
InsomniaPsychiatric disorders86/207

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Hodgkin's/Non-Hodgkin's Lymphoma (≤ 65 Years)Hodgkin's/Non-Hodgkin's Lymphoma (> 65 Years)Total
Years46.5 ± 13.168.5 ± 2.348.5 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)Hodgkin's/Non-Hodgkin's Lymphoma (≤ 65 Years)Hodgkin's/Non-Hodgkin's Lymphoma (> 65 Years)Total
Female66268
Male12217139
08

Study locations

42 sites
  • University of Alabama in Birmingham
    Birmingham, Alabama 35294, United States
  • Arizona Cancer Center
    Tucson, Arizona 85719, United States
  • Alta Bates Summit Medical Center
    Berkeley, California 94704, United States
  • Scripps Clinic
    La Jolla, California 92037, United States
  • UCSD Medical Center BMT Program
    La Jolla, California 92093, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Sutter Cancer Center
    Sacramento, California 95816, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • University of California San Francisco Medical Center
    San Francisco, California 94143, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Florida Hospital Cancer Institute
    Orlando, Florida 32804, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • University of Illinois Cancer Center
    Chicago, Illinois 60612, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • Loyola University Chicago
    Maywood, Illinois 60153, United States
  • Bone Marrow and Stem Cell Transplant Program
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center
    Westwood, Kansas 66205, United States
  • LSU Health Sciences Center at Shreveport/Feist Weiller Cancer Center
    Shreveport, Louisiana 71103, United States
  • University of Maryland Medical Center - Marlene & Stewart Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Montefiore-Einstein Cancer Center
    Bronx, New York 10467, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • The Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • South Texas Veterans Health Care System
    San Antonio, Texas 78229, United States
  • Texas Transplant Physician Group, PLLC
    San Antonio, Texas 78229, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • West Virginia University Hospital
    Morgantown, West Virginia 26506, United States
  • Saint John Regional Hospital
    Saint John, New Brunswick E2L 4L2, Canada
  • Queen Elizabeth II Health Sciences Centre - VG Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Royal Victoria Hospital MUHC
    Montreal, Quebec H3A 1A1, Canada
  • Saskatoon Cancer Centre
    Saskatoon, Saskatchewan S7N 4H4, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of May 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2009
First posted
Jul 29, 2009
Start
Jan 2010
Primary completionActual
May 2013
CompletionActual
Jun 2013
Results first posted
Jul 31, 2014
Last update
Jul 31, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00948090
Collaborators
Center for International Blood and Marrow Transplant Research
Responsible party
Sponsor
First posted
Jul 29, 2009
Start date
Jan 2010
Primary completion
May 2013
Completion
Jun 2013
Results posted
Jul 31, 2014
Last update
Jul 31, 2014

Study contacts

Agnes Elekes, MD
study director · Otsuka Pharmaceutical Development and commercialization

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Busulfan · Cyclophosphamide · Etoposide

Start the discussion